| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.4 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | AG-014699 | GDSC1000 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.5 |